EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

What are the right endpoints to assess the effectiveness of new treatments for IgAN?

Niels Jongs, Hiddo J L Heerspink iD

Nephrology Dialysis Transplantation · 2026

DOI: 10.1093/ndt/gfaf184 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nephrology Dialysis Transplantation, 2026. Verfasst von Niels Jongs und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. Hauptthemen laut MEDLINE: Glomerulonephritis, IGA, Proteinuria, Endpoint Determination. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Otsuka America Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunoglobulin A nephropathy (IgAN) is a glomerular disease associated with a rapid estimated glomerular filtration rate (eGFR) decline, especially in the presence of severe proteinuria. The change in proteinuria and eGFR slope are accepted surrogate endpoints in clinical trials to establish the efficacy of new interventions for patients with IgAN. Proteinuria is an established surrogate marker for disease progression, with higher levels correlating with worse long-term outcomes. Meta-analyses have demonstrated that treatment effects on proteinuria over 6–9 months correlate with treatment effects on eGFR slope. The eGFR slope, particularly over 2–3 years, provides an indicator of renal function decline and long-term prognosis. Studies have demonstrated robust associations between treatment effects on eGFR slope and clinical kidney outcomes. Based on these studies, recent regulatory considerations support proteinuria change and eGFR slope as clinical trial endpoints for accelerated approval in IgAN trials, allowing for earlier assessment of treatment efficacy. Future trials can leverage these markers to streamline drug development, providing robust and timely evaluations of novel therapies. This review summarizes recent advances in the validation of clinical trial endpoints in IgAN and concludes with new developments in this area.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerulonephritis, IGAProteinuriaEndpoint DeterminationHumansGlomerular Filtration RateBiomarkersPrognosisClinical Trials as TopicDisease Progression

Stichwörter der Autor:innen

albuminuriaclinical trialeGFRimmunoglobulin A nephropathyproteinuria

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

ORCID-Profile: Hiddo J L Heerspink

Förderung

  • Otsuka America Pharmaceutical

Zitieren

APA

Jongs, N., & Heerspink, H. J. L. (2026). What are the right endpoints to assess the effectiveness of new treatments for IgAN?. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfaf184

Vancouver

Jongs N, Heerspink HJL. What are the right endpoints to assess the effectiveness of new treatments for IgAN?. Nephrology Dialysis Transplantation. 2026. doi:10.1093/ndt/gfaf184

BibTeX
@article{Jongs2026,
  author = {Jongs, Niels and Heerspink, Hiddo J L},
  title = {What are the right endpoints to assess the effectiveness of new treatments for IgAN?},
  journal = {Nephrology Dialysis Transplantation},
  year = {2026},
  doi = {10.1093/ndt/gfaf184}
}
Kostenlos starten →